![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 1
Zeitschriftenartikel
Schmid, Irene 
ORCID: https://orcid.org/0000-0002-5105-3597; O’Neill, Allison F.; Watanabe, Kenichiro ORCID: https://orcid.org/0000-0002-8892-3082; Aerts, Isabelle; Branchereau, Sophie; Brock, Penelope R. ORCID: https://orcid.org/0000-0003-1239-6316; Dandapani, Madhumita; Fresneau, Brice ORCID: https://orcid.org/0000-0001-7603-7828; Geller, Jim; Hishiki, Tomoro; Ingham, Danielle ORCID: https://orcid.org/0009-0008-0671-7287; Kraal, Kathelijne; Ronghe, Milind ORCID: https://orcid.org/0000-0002-1865-9335; Tiao, Greg; Trobaugh-Lotrario, Angela; Rangaswami, Arun; Sullivan, Michael J.; Zsiros, Jozsef; Hiyama, Eiso; Malogolowkin, Marcio und Ansari, Marc
(2025):
Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure.
In: EJC Paediatric Oncology, Bd. 5, 100235
[PDF, 6MB]
ORCID: https://orcid.org/0000-0002-5105-3597; O’Neill, Allison F.; Watanabe, Kenichiro ORCID: https://orcid.org/0000-0002-8892-3082; Aerts, Isabelle; Branchereau, Sophie; Brock, Penelope R. ORCID: https://orcid.org/0000-0003-1239-6316; Dandapani, Madhumita; Fresneau, Brice ORCID: https://orcid.org/0000-0001-7603-7828; Geller, Jim; Hishiki, Tomoro; Ingham, Danielle ORCID: https://orcid.org/0009-0008-0671-7287; Kraal, Kathelijne; Ronghe, Milind ORCID: https://orcid.org/0000-0002-1865-9335; Tiao, Greg; Trobaugh-Lotrario, Angela; Rangaswami, Arun; Sullivan, Michael J.; Zsiros, Jozsef; Hiyama, Eiso; Malogolowkin, Marcio und Ansari, Marc
(2025):
Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure.
In: EJC Paediatric Oncology, Bd. 5, 100235
[PDF, 6MB]